Skip to search formSkip to main contentSkip to account menu

repaglinide

Known as: Repaglinida, repa-glinide, Repaglinidum 
A nonsulfonylurea insulin secretagogue belonging to the melgitinide class with hypoglycemic activity. Repaglinide is rapidly absorbed and has a rapid… 
National Institutes of Health

Related topics

Related topics

15 relations

Narrower (4)

AG-EE 388 ZWAG-EE 623 ZWPrandiMetPrandin

Broader (3)

CarbamatesHypoglycemic AgentsPiperidines
Diabetes Mellitus, Insulin-DependentDiabetes Mellitus, Non-Insulin-DependentDiabetic KetoacidosisDrug Allergy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport.
The predictive power of using in vitro systems in combination with physiologically based pharmacokinetic (PBPK) modeling to… 
Highly Cited
2008
Highly Cited
2008
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
Objective Organic anion transporting polypeptide 1B1 (OATP1B1), encoded by SLCO1B1, is an influx transporter expressed on the… 
2004
2004
Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes.
2001
2001
Repaglinide-induced factitious hypoglycemia.
We report the first case of repaglinide-induced factitious hypoglycemia in a young male. This case posed a challenging diagnostic… 
Review
2000
Review
2000
Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often… 
Highly Cited
2000
Highly Cited
2000
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
OBJECTIVE This multicenter open-label clinical trial compared the efficacy and safety of repaglinide/troglitazone combination… 
Review
2000
Review
2000
Pharmacology and clinical experience with repaglinide
Repaglinide (NovoNorm®) is a novel oral antidiabetic agent, the first of a new class of insulin secretagogues known as the… 
2000
2000
The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.
This study investigated plasma protein binding by the novel oral hypoglycemic agent, repaglinide, and assessed the influence of… 
Review
1999
Review
1999
The use of insulin secretagogues in the treatment of type 2 diabetes.
1996
1996
Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets.
The meglitinide analogue repaglinide is a novel non-sulphonylurea insulinotropic agent which, like hypoglycaemic sulphonylureas… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)